Review Article
Open Access

A technical view on transporters-the drug pharmacokinetics dictators

Abstract

In any of the cases administrating drugs by the oral/parenteral route, the medication should achieve the objective site before that; absorption and distribution have an unadorned job. For a process to occur there will be an assisted mediator's means that makes the action possible and effective. In that transporters of drugs are recognized as key players in the entire drug life that entered after administration. The specific influx and efflux transporters in organs accountable for drug biotransformation and evacuation give transporter proteins a unique porter function in regulating drug entree to processing enzymes and excretory paths. This review highlights to make understand about the diverse kinds of transporters on various sites of the body that are involved in pharmacokinetic parameters, including bioavailability, exposure, Volume of distribution, clearance, and half-life, for orally dosed drugs. And this explanation clears the difference between each transporter.

Keywords: ttransporter, biotransformation, influx, efflux, pharmacocinetiques

Volume 6 Issue 4 - 2019

Anusha GollaBala, Hindustan Abdul Ahad, Haranath Chintaginjala, Suryaprakash Reddy Chapidi, Kalpana Kodi
Department of Pharmaceutics & Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research, India

Correspondence: Hindustan Abdul Ahad, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Ananthapuramu – 515721 Andhra Pradesh, India, Email abdulhindustan@gmail.com

Received: April 26, 2019 | **Published:** August 12, 2019

Abbreviations: ASBT, Apical Sodium dependent Bile salt Transporter; ATP, Adenosine Tri Phosphate; BCRP, Breast Cancer Resistance Protein; CNT, Concentrative Nucleoside Transporters; ENT, Equilibrative Nucleoside Transporters; MCT, Monocarboxylate Transporters; MDR, Multi Drug Resistance protein; MRP, Multidrug Resistance associated Proteins; OAT, Organic Anion Transporter; OATP, Organic Anion Transporting Polypeptides; OCT, Organic Cation Transporter; OCTN, Organic zwitterionic Cation Transporter; OST, Organic Solute Transporter; PEPT, Human Peptide Transporter; P-gp, P-glycoprotein; SLC, Solute Carrier; SLCO, Solute Carrier Organic Anion; SNP, Single Nucleotide Polymorphisms; TEA, Tetraethyl Ammonium.

Introduction

The reason behind the non-linearity of many drugs came to an end with the discovery of wide varieties of transporters that are segregated on different regions of living tissue. Some transporters hasten and facilitate the entrance of drugs into the target cells called influx transporters, while few slow down and oppose the entry called efflux transporters. Both influx and efflux transporters are vital in deciding medicine's temperament by regulating the availability of the drug in the blood. The major uptake transporters accountable for drug conveyance fit to the 2 solute transferors namely Solute Carrier Transporters (SLC) and Solute Carrier Organic Anion (SLCO) superfamilies.[1–3] These are of antiporter, antiporter, or symporter in nature, but they are not fully elucidated.[4] Overall, they didn't feat energy except a chemi-osmotic incline shaped by transferring drugs into cells.

SLC super family transporters

a. The different transporters belong to SLC super family transporters are as follows[5–7]
b. Organic Anion Transporters (OAT)
c. Organic Cation Transporters (OCT)
d. Electro Neutral Organic Cation Transporters (OCTN)
e. Equilibrate Nucleoside Transporters (ENT)
f. Concentrative nucleoside transporters (CNT)
g. Apical Na+dependent bile salt transporter (ASBT)
h. Mono Carboxylate Transporters (MCT)
i. Peptide Transporters (PEPT)

SLCO family transporters

a) The different transporters belong to SLCO super family transporters are as follows[8]
b) Organic Anion Transporting Polypeptides (OATP)
c) P-glycoprotein (Pgp)
d) Multidrug Resistance Proteins (MRP1- 6)
e) Breast Cancer Resistance Protein (BCRP)

Listed transporters under SLC and SLCO super families are shown in Table 1. All these transporters need Adenosine Tri-Phosphate (ATP) as an energy source, letting the drug molecules to enter against the concentration gradient. The intestinal absorption of drugs is mostly ruled by its disbanding features, permeability, and stability of the drug on exposure to the stomach walls. Transporters which intake drugs called as influx and expel out called efflux transporters, which are present on cell membranes. Interchange of these transporters collected with drug metabolism may need for the consecutive cross of these membranes.[9] The commonly the transporter are generalized as follows.

Facilitative transporters

These help in the moment of a single solute down passively without the need of energy.[10]

Active transporters

Transporters which helps in transporting drugs in contradiction of an electrochemical gradient with the aid of energy. The active transporters are further categorized as follows.[11]

Ion pumps

These transporters join with energy generating constituents. In many circumstances, these systems produce electric charges transversely on the cell membrane.

Secondary active transporters

These transporters utilize the electric currents and ion concentrations created by the active transporters.

Co-transporters (symporters)

They change ≤ 2 dissimilar drugs in a similar route.

Antiporter

They move ≤ 2 dissimilar drugs in conflicting orders, abusing a chemical ascent for the solute.

Table 1 Transporters of SLC and SLCO super families

SLC super family	SLCO super family
MCT1	OATP1A2
PEPT1	OATP1B1
PEPT2	OATP1B3
3-Oct	OATP2B1
ASBT	OATP1B3
CNT	OATP1B1
CNT2	OATP4A1
OCTN1	OATP3A1
OCTN2	OATP2B1
OCT1	MRP
OCT2	BCRP
ENT1	P-gp
ENT2	
NTCP	

Role of transporters in pharmacokinetics

1. Transporters show a vivacious role in controlling the moment of drug molecules in/out of the cells.[12–14]
2. The orally given drug dissolved, signs the intestinal wall (Figure 1), later extends the liver via portal circulation and enters into the blood, finally distributes in numerous tissues.
3. The drug is removed from the circulation in the liver then into the urine.
4. In the ADME developments, a drug permits over numerous biotic membranes.
5. The force of drug drive over these layers is exaggerated by the biological possessions of a drug.
6. These transporters have a vital character in enabling or averting drug movement.

Pharmacokinetics at each organ level: While a diverse set of organs and tissues are regulated by transporters, there are some similarities in how transporters function. Efflux transporters expressed on the basolateral side of epithelia extrude drugs from organs back into plasma, while basolateral influx transporters move drugs from the blood into the epithelia. Apical efflux transporters extrude drugs into bile/urine/ tissues, while apical influx transporters bring drugs from the lumen of the excretory organs into the epithelia or out of tissues into the epithelia. In this way, both influx and efflux transporters influence ADME and disposition of endogenous substrates. Endothelial and hematopoietic transporters also act as gate keepers that regulate the tissue concentrations of drugs and primarily serve a protective function by limiting tissue exposure to certain substrates



Figure 1 Transporters at Intestinal epithelia

Gut

The gut wall is composed of quite a lot of transporters that are expressed on the luminal membrane of enterocytes, including efflux transporters (e.g. ABCB1, ABCG2, ABCC2) and influx transporters (e.g. PEPT1, OATP2B1, OATP1A2) although uptake transporters are rather poorly characterized. Efflux transporters limit the absorption of various toxins in the gut lumen while influx transporters increase absorption of certain drugs. The interplay between these transporters, however, is complex. For instance, a decline in an antihistaminic drug exposure was observed when orally administered was administered with grapefruit sap. This observation was unexpected given that the drug is a substrate of ABCB1 and inhibition of ABCB1 with grapefruit sap was thought to increase the drug exposure by blocking its efflux into the lumen of the gut. It was later determined, however, that grapefruit sap also blocks the influx transporter OATP1A2 thereby decreasing the oral absorption of this drug. However, little is known about how genetic variation in SLCO1A2 (encoding OATP1A2) affects the pharmacokinetics and therapeutic effects of its substrates. Transporter expression in the gut is therefore based on pharmacotherapy and may influence relationships between polymorphisms and inter individual variation in drug disposition and outcomes.

Liver

In the liver, influx transporters of the SLC family act to uptake drugs into hepatocytes where metabolism occurs. Efflux transporters,

primarily ATP-dependent transporters that are located at the canalicualar or sinusoidal membrane of hepatocytes, then act to export the drugs and their metabolites back into the blood or into the bile. Both influx and efflux transporters play a critical role in drug metabolism and clearance. For instance, statin metabolism and elimination is largely governed by how rapidly the liver is proficient to uptake, metabolize, and then clear these drugs.

Kidney

Proximal tubule epithelia express tight junctions that edge substrate diffusion; thus transporters are vital mediators of renal elimination pathways. Influx transporters, including OATPs, OATs, and OCTs transport substrates into the renal epithelial cell while various MRPs transport substrates back into the bloodstream. Equilibrative nucleoside transporter function as bidirectional receptors at the basolateral membrane. Luminal efflux transporters, such as ABCs, MRPS, and MATEs, efflux substrates into the lumen. Other transporters, such as OATPs, OATs, OCTNs, CNTs, PEPTs and others, pump drugs into the lumen, remove drugs from the lumen, or function as bidirectional pumps.

Endothelial barriers

There are multiple blood-tissue barriers that shelter various tissues from circulating blood. Perhaps the best-known barrier is the BBB, which significantly limits the penetration of myriad substances into the CNS. The BBB is quite impermeable to the penetration of drugs, due to the presence of tight junctions between cells and the high expression of efflux transporters (i.e. P-glycoprotein) on the luminal membrane of the endothelial cells. Other blood-tissue barriers, however, can be more readily penetrated by various drugs. For instance, the blood-nerve-barrier (BNB) is composed of the endoneurial microvasculature and the innermost layers of the perineurium. Peripheral nerve micro vascular endothelial cells (PnMECs) constitute the main interface between the peripheral nerves and the blood. PnMECs express P-glycoprotein, however, alterations to P-glycoprotein activity greatly increase drug penetration into the nerve, whereas the brain is less affected by decreased P-glycoprotein activity and remains highly impermeable to drug. Similarly, P-glycoprotein is expressed in the endothelium of the heart and other tissues that are more permeable toward circulating ABCB1 substrates.

Hematopoietic cells

Nearly all hematopoietic cells express drug transporters that regulate various end biotic processes, alter paracrine signaling, and can confer resistance to therapeutics in normal and diseased (e.g., HIV-infected or cancerous) cells. In normal lymphocytes ABCB1 expression ranges from 20–80% of B cells and 30–100% of T-cells, whereas approximately 40–65% of leukocytes express ABCB1. Monocytic expression of ABCB1 has been problematic for HIV therapeutics that is substrates of ABCB1; this is especially true for anti retroviral that induce ABCB1 expression in target cells. ABCB1 over expression is also a problem in the treatment of leukemia. Some estimate that 45% of patients with newly diagnosed AML over express ABCB1, while 65% of patients with refractory AML over express ABCB1. ABCB1 effluxes multiple therapeutics used to treat AML. However, ABCB1 also protects hematopoietic cells from cytotoxicity of certain anticancer therapies. For instance, taxanes can cause severe neutropenia, and higher ABCB1 expression appears to have a protective effect. Polymorphisms in ABCB1 and ABCG2 have been linked to differential transport of substrates in hematopoietic cells. These studies consistently found that carriers of ABCB1 variant alleles have lower expression and function of ABCB1 in multiple cell populations. Studies in mice lacking various ABC transporters demonstrated that normal physiological processes were interrupted while certain hematopoietic cells were more susceptible to drug-induced toxicity. Therefore, ABCB1 variants alter the physiology, disease, and treatment with agents that target or cause undesirable toxicity in hematopoietic cells.

SLC and SLCO super family transporter's structural moieties responsible for drug disposition

Productive application of structure-based drug design methods includes the characterization of SLC structures in different conformational states and the description of their mode of interaction with small molecules and ions. Recent advancements in experimental techniques such as X-ray crystallography, electron microscopy, and NMR, as well as improved computational methods and computer power, have facilitated the characterization of human SLC transporters with structure-based approaches, as demonstrated by the growing number of such published studies. Currently there are experimentally determined high-resolution structures of only four human SLC members representing three human SLC families. They include the Glucose transporters GLUT119 and GLUT320 (SLC2A1 and SLC2A3, respectively), the Anion exchanger (AE1; SLC4A1), and the ammonium channel or Rh protein (RhCG; SLC42A3). However, in recent years there has also been a surge in the number of atomic structures of SLC homologs from a variety of eukaryotes (e.g. the Drosophila dopamine transporter DAT (SLC6A4)) and prokaryotes (e.g., the She wanellaoneidensis di-/tri- peptide transporter PEPTso (an SLC15 homolog)). Many of these structures share sequence identity of ~30% or more and conserved binding site with their human homologs, thereby providing useful templates for elucidating the substrate specificity of the human SLC members. The members of the organic anion transporting polypeptide super family (OATPs) are classified within the SLCO solute carrier family.

All functionally well characterized members are predicted to have 12 transmembrane domains and are sodium-independent transport systems that mediate the transport of a broad range of endo- as well as xenobiotics. Substrates are mainly amphipathic organic anions with a molecular weight of more than 300 Da, but some of the known transported substrates are also neutral or even positively charged. Among the well characterized substrates are numerous drugs including statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and antibiotics, antihistaminic, antihypertensive and anticancer drugs. Based on their amino acid sequence identities, the different OATPs cluster into families (in general with more than 40% amino acid sequence identity) and subfamilies (more than 60% amino acid identity). With the sequencing of genomes from different species and the computerized prediction of encoded proteins more than 300 OATPs can be found in the databases, however only a fraction of them have been identified in humans, rodents, and some additional species important for pharmaceutical research like the rhesus monkey (*Macacamulatta*), the dog (*Canis lupus familiaris*) and the pig (*Susscrofa*). These OATPs form 6 families (OATP1–OATP6) and 13 subfamilies. In this review we try to summarize what is currently known about OATPs with respect to endogenous substrates, tissue distribution, transport mechanisms, regulation of expression, structure–function relationship and mutations and polymorphisms.

Transporters for drug absorption

ASBT (Apical Sodium Bile acid Transporter)

It has both influx and efflux mechanism. It was first replicated from hamster ileum and humans. It is restricted on intestinal epithelium and the liver cells. The transporter is electrogenic[15–17] joined with sodium in 2:1 (sodium: bile acid). Human ASBT (hASBT) seemingly works as a monomer, while some indication proposes the presence of a dimer. hASBT is abundant in the ileum, renal proximal tubules, and Biliary epithelium. QSAR discovered one H_2 bond donor, one H_2 bond acceptor, a negative charge; 3 hydrophobic centers are accountable for the action of ASBT. A congenital alteration in hASBT upshot in mainly bile acid mal absorption syndrome, representing the hASBT is the main tool for intestinal reabsorption of bile acids. Structural evidence on hASBT is partial to its main structure and membrane topology. While detailed evidence about the substrate binding domains of hASBT is not accessible so far, its structural and functional issues have been deliberated with numerous biophysical approaches. Photo affinity labeling and enzymatic digestion specify that the drug tie area of hASBT is confined to the 7th transmembraneprovince and the C-terminus at 56-67 amino acids. Additionally few more proofs proposed the presence of 4 separate binding sites founded on a 3-D structure of hASB Test ablished in silico by homology demonstrating.

BCRP (Breast Cancer Resistance Protein)

BCRP is abundant in the placenta, Blood Brain Barrier (BBB), the liver, intestine, adrenal gland, and testes, where it pullback drugs athwart from membrane.[18] In gut BCRP limits the intestinal uptake of some drugs viz., Antibiotics and Sulfasalazine. It is tangled in both renal drug evacuation and biliary emission. Several SNPs and at least one insertion-deletion variant have been identified. The overtone among these SNPs and BCRP countenance levels and pharmacokinetics is uncertain.

hPepT1 (Human peptide transporter)

The hPepT1 is a popular influx transporter, has very low empathy and high capability. Majorly it involves in the oligopeptide transporter system. The acidic pH created by the brush-border Na+/H+ exchanger helps in the intestinal absorption of peptide drugs. Different types of are noted to existed for this transporter. The penetration through the membrane be contingent on an apical H+/ dipeptide transporter (hPepT1), subsequently inflowing the enterocytes, the proteins which unaffected for hydrolysis are elated athwart the basolateral layer by an H+ autonomous transporter, perhaps hPepT2. The hPepT1 present on the apical membrane and the hPepT2 is contained on the basolateral membrane exterior. The mass of hPepT1 upsurges from beginning till the end of the small intestine (abundant at the villi). Its appearance is controlled by dietary eminence (amassed in fasting). It is also comparatively genuine by many drugs that unfavorably disturb the purpose of other transporters. This remark has elevated the proposal that drugs whose absorption is connected to hPepT1 may show less eroticism throughout therapy than the drugs allied less healthy transporterappliance.[19–21] Certain hPepT1, SAR was detected. Consequently, some exclusion like ACE inhibitors shows the mentioned topographies.

a. A free C- end –COOH for hydrogen bonding
b. An $–NH_2$ at N-terminal
c. Molecules with Zwitterions
d. L-configuration of an amino acid at C-end

The amalgam engrossed by the dipeptide transporters display a saturable preoccupation. Subsequently, drug gastric absorption (Pw) is expressed as Equation 1 & 2.

$$Pw = \frac{Jmax}{Km + Cw} + Pm \ldots . (1)$$

$$Pw = \frac{Pc}{1 + \left(\frac{Cw}{Km}\right)} + Pm \ldots . (2)$$

Where,

J_{max} - Maximum transport rate

C_w - Intestinal wall concentration

K_m - The molar concentration of substrate at ½ J_{max}

Pc - The permeability by the carrier-mediated transport

Pm - The intestinal permeability attributable to passive diffusion.

MDR (Multi Drug Resistance Protein): MDR is a well-known efflux transporter, present in many human cells with an utmost countenance at the surface of red cells, hepatic cellular lines (Figure 2), and the kidney. In these tissues, MDR1 helps to control the ADME of a multitude of exogenous substrates. MDR1 is also localized in hematopoietic stem cells, BBB, the heart, neurons, and the placenta.[22–24] MDR1 effluxes drugs, and limits the diffusion of toxins. Holotype examination discloses adding actions of these SNPs on MDR1 purpose. Sixty-four MDR1 heliotypes which comprise the 3 earlier stated SNPs; thus, haplotype structure indicate more bonding with other useful polymorphisms.[25]



Figure 2 Transporters at Hepatocytes

MRP (Multidrug resistance-associated protein): MRP is articulated in many cells viz., intestine, hepatocytes, BBB, proximal tubules, and placenta. MRP is confined to the apical membrane of the epithelial cell. It vigorously transfers anionic drug complexes and free drugs, in this way helps in cleansing. Additionally, MRP2 shows the main part of transporting antineoplastic substances. For instance, in vitro evaluations designate that MRP2 is specified at greater quantities in Tamoxifenresilient breast cancer tissues, signifying a part for MRP2 in conveying the active metabolites of Tamoxifen. Most

MRP2 polymorphisms are quite rare in the overall populace. This review covers MRP1 because few studies assessed consequences of polymorphisms in this gene and those that have unsuccessful to find any useful important properties.[26]

Organic Anions and Cations as transporters: An amphiphilic solute organizer family with the ability to transport organic anions and cations has been recently well-established but, their full scope of gastric consequence has still to be dogged. The transporters of this type are diverse, demonstrating several features as follows.[27]

- A Na^+ independent Thiamin Transporter
- A Na^+ independent and Potential-Dependent Transporter, that arbitrates moment of Tyramine
- A Na^+ independent and Potential-Independent Transporter, that arbitrates the moment of Choline and may be complicated in the ooze of organic ions over an organic cationic argument
- A proton/ cation antiporter
- P-gp that arbitrates emission of hydrophobic cations
- A polyamine transporter

OATP (Organic Anionic Transporting Polypeptide)

OATP is an influx transporter, majorly located in the epithelial cells of the intestine, hepatocytes, alveolar cells, proximal convoluted tubules (Figure 3) and BBB. OATPs control the cellular acceptance of numerous endogenous compounds and drugs.



Figure 3 Transporters at Kidney's proximal convoluted tubules

Meta pharmacophore models classify numerous hydrophobic features; two hydrogen bond acceptors are the requisites for its efficacy. It is a very vast family with a different replica of moieties such as OATP1A1, OATP1A2, OATP1A3, OATP1A4, OATP1A5, OATP1B1, OATP1B2, and OATP1B3. The OATP1B1 is a hepatic influx transporter.[28] Till date, over 40 non-synonymous SNPs (Single Nucleotide Polymorphisms) has been recognized on (encoding OATP1B1). Like OATP1B1, OATP1B3 is the liver precise influx transporter that transfers drugs across the membrane into the hepatocytes. Structural modeling suggests that a specific amino acid faces the supposed central aperture of the transport protein that is believed to be vital for the translocation of drugs.

OCT (Organic Cation Transporter)

The OCT has been molecularly recognized in rodents and humans. They conveyance an assortment of cationic drugs like Tetraethyl ammonium, Choline, Neurotoxin 1 methyl-4- phenyl pyridinium, and other cationic compounds. Rat OCT3 and human OCT2 are stated in the brain, but it is believed that they contribute to the ruling of neurotransmitters in neurons than at the BBB (Figure 4). A new type of organic cation/carnitine transporters (OCTN1-3) from OCTN2 was also replicated. The amino acid arrangements of OCTN1, OCTN2, and OCTN3 articulate less but the noteworthy resemblance to those of OCT type, and OCTNs was primarily believed to be organic cation transporters. Pharmacophore models revealed that three hydrophobic features and one positive moiety are responsible for its action. It is most intricate in anticancer reabsorption.[29]



Figure 4 Transporters at Blood-Brain barrier

P-gp (Plasma glycoprotein)

It is an ATP depended on an efflux transporter and transports a wide range of substances out of the cell. The main reason for the MDR of cancer cells due to a decrease in the accumulation of anti-tumor drugs by propelling them out of the tissues. It is considered by broad drug specificity, including anti-tumor drugs, Ca^+ channel blockers, and immune suppressants by ATP-based main active transport as the ABC (ATP-binding cassette) transporter. P-gpis found in various cells of the body with drug efflux activity. In mice lacking a 'mdrla' gene product, the distribution of Vinblastine was improved in many cells mainly of the brain. Gastric absorption of these drugs was also augmented in those, which is reliable with previous detections that P-gp is restricted on the luminal membrane of the intestine and transports certain peptides out into the lumen.[30–32] P-Adrenoceptor antagonists reported varying in their aptitude to be absorbed by the intestine liable partly on their lipophilicity. Based on the correlations between gastric absorption and lipid solubility, some K+-blockers, have unpredictably low porousness across the intestinal epithelium. The degree of the influence of P-gparbitratedexcretion of K+-blockers *in vivo*, though, leftovers to be elucidated. QSAR model revealed that 2 H-bond acceptors and two hydrophobic moieties are responsible for its action.

Conclusion

The drug movement across the biological membranes modulated with drug transporters is gaining importance since the last few years. These drug transporters play a vital role in the disposition of drugs and their biological activity. Drug influx or efflux with these transporters lead to untoward unexpected actions which may lead to organ-specific toxicity due to drug accumulation or clinically useless because of unabsorbed drug. These disturbances in drug bioavailability and bioequivalence approaches like drug inhibitors with structural similarities with drugs were elevated and many pieces of research under the process. Gaining knowledge about this information about drug transporters for the development of drugs with superior ability and reduced side effects. Finally, it was concluded that drug transporters proved to be remarkably vital in health care and optimal drug therapy.

Acknowledgments

The authors are thankful to Prof. Y. Padmanabha Reddy, Principal, RIPER, Ananthapuramu for providing facilities for perusing this work.

Conflicts of interest

No conflict of interest was declared by the authors.

References

1. Balakrishnan A, Polli JE. ASBT, SLC10A2: a potential prodrug target. *Molecular pharmaceutics.* 2006;3(3):223−230.
2. Joseph WP, Patrick J. Sinko. Drug Transporters: Integration in Understanding ADME, *Euro J Pharm Sci.* 2006;27(5):391−560.
3. Sandeep KV, NusrathF, Chandrakala L, et al. Role of drug transporters and heat shock proteins during ethanol exposure to human neural precursor cells and its lineages. *Tissue and Cell.* 2018;51:14−23.
4. Weibin Z. Transporter-mediated natural product–drug interactions for the treatment of CV diseases. *J of Food and Drug Analysis.* 2018;26(2):S32−S44.
5. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes. *Drug metabolism and disposition*. 2003;31(12):1507−1519.
6. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. *Phar res*. 2009;26(9):2039−54.
7. Bi Y, Mathialagan S, Tylaska L, et al. Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug. *J PharmacolExpTher*. 2018;364(3):390−398.
8. Kunimatsu S, Mizuno T, Fukudo M. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats. *Drug MetabDispos*. 2013;41(8):1592−1597.
9. .Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim. Biophys. Acta.* 1976;455:152–162.
10. Guofeng Y. Drug Transporters: Molecular Mechanisms, Novel Modes of Regulations, and Therapeutic Strategies. *Advanced Drug Delivery Reviews.* 2017;116:1–118.
11. Ford JM. Experimental reversal of P-gp mediated MDR by pharmacological chemosensitizers. *Eur J Cancer*.1996;32A:991–1001.
12. Ali HM. Reduced ampicillin bioavailability following oral co-administration with chloroquine. *J AntimicrobChemother.* 1985;15(6):781–784.
13. Kalinkova GN. Studies of beneficial interactions between active medicaments and excipients in pharmaceutical formulations. *Int J Pharm.* 1999;187(1):1−15.
14. Poli JE. *In vitro–in vivo* relationship of several “immediate release” tablets containing narrow permeability drugs. *AdvExp Med Biol.* 1997;423:191–198.
15. Midha KK, Rawson MJ, Hubbard JW. Prescribability and switchability of highly variable drugs and drug products. *J Control Release.* 1999;62(1−2):33−40.
16. AmidonGL, LennernasH, ShahVP, et al. A theoretical basis for a BCS: the correlation of *in vitro* drug product dissolution and in vivo bioavailability. *Pharm Res.* 1995;12(3):413−420.
17. SeydelJK, Schaper KJ. Quantitative structure-pharmacokinetic relationships and drug design. *Pharmacol Ther.* 1982;15:131−182.
18. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. *ProcNatlAcadSci.* 1998;95:15665–15670.
19. Hagenbuch B, Gui C. Xenobiotic transporters of the human OATP family. *Xenobiotica.* 2008;38(7−8):778–801.
20. Yu LX, Crison JR, Lipka E. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. *Adv Drug Deliv Rev.* 1996;19(3):359−376.
21. MakheyVD, GuoA, Norris DA, et al. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and Caco-2 cells. *Pharm Res.* 1998;15(8):1160−1167.
22. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. *Eur J ClinPharmacol.* 2003;58(12):809–812.
23. Cordon CC, Brien JP, Casals D, et al. MDR gene P-gp is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci*. 1989;86(2):695–698.
24. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the hABCB1, MDR1, gene. *Pharmacogenetics.* 2003;13(8):481–494.
25. Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72(5):648–672.
26. Mottino A, Hoffman T, Jennes L, et al. Expression of multidrug resistance-associated protein 2 in the small intestine from pregnant and postpartum rats. *Am J Physiol Gastrointest Liver Physiol.* 2001;280(6):G1261−G1273.
27. FDA. *In vitro* metabolism - and transporter mediated drug-drug interaction studies (draft guidance). 2017.
28. Colas C, Pajor AM, Schlessinger A. Structure Based Identification of Inhibitors for the SLC13 Family of Na(+)/DicarboxylateCotransporters. *Biochemistry,* 2015;54(31):4900−8.
29. Canul JC, Assal R, Cirri E, et al. Structure and allosteric inhibition of excitatory amino acid transporter. *Nature*. 2017;544(7651); 446−51.
30. Kilbourn MR. Small molecule pet tracers for transporter imaging. *Semin Nucl Med*. 2017;47:536–552.
31. Miller DS. Regulation of ABC transportersblood-brainbarrier the good the bad and the ugly. *Adv cancer res*. 2015;125:43–70.
32. Pan Y, Hsu V, Grimstein M, et al. The application of physiologicallybasedpharmacokineticmodeling to predict the role of drugtransporters: scientific and regulatory perspectives. *J Clin Pharmacol*. 2016;56:S122–S131.